Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

Net Loss: For the first quarter of 2025, the Company generated a net loss attributable to its shareholders of $19.6 million, ...

One participant with a history of hepatitis C, hepatitis B, human immunodeficiency virus ... bleeding event occurred in a nontarget joint (i.e., a joint without repeated bleeding and without ...

District Medical and Health Officer (DMHO) Dr Durga Rao Dora confirmed 19 Hepatitis B Surface Antigen (HBSAG) cases and nine Hepatitis C Virus (HCV) infections after a large-scale screening of ...

Introduction: For complete or functional cure of hepatitis B virus (HBV) infection ... can also elicit DC maturation and augment cross presentation of antigens in DCs, resulting in NK cell-mediated ...

5 Year Ago - 2020-03-17 00:00:00 Debmarine-Namdeb Foundation manager Imme Hucke-Mcfarlane says the impact hepatitis E has had in Namibia highlights the importance to join in the fight against the ...

Peginterferon can be given conveniently with weekly dosing, and its effect on hepatitis B e antigen seroconversion is highly durable. However, it carries numerous side effects and the treatment is ...

Chronic infection with hepatitis virus is etiologically linked ... identify specific antigens related to the infective organism and demonstrate the presence of an infective organism or its antigen ...